Matthias Bodenstedt

CFO Matthias Bodenstedt sells 39.1K MLTX shares at $22.04 via scheduled 10b5-1 plan; stock down 66.2% from 52-week high, company unprofitable.

CFO Matthias Bodenstedt sold 39,120 shares at $22.04 on 2026-06-22 under a pre-arranged 10b5-1 trading plan adopted 2025-12-10, reducing holdings from 1,154,555 to 1,115,435 shares. The transaction is scheduled rather than discretionary. MoonLake Immunotherapeutics is currently unprofitable with net income of $-69,707,000.00 and the stock is trading 66.2% below its 52-week high of $62.75. Bodenstedt's prior trades at MLTX show mixed outcomes: his April 2026 sells declined 12.6% and 9.9% over 30 days, though an October 2025 buy gained 16.9% and 22.9% over 30 and 90 days respectively. The scheduled nature of this transaction limits inference about timing or conviction, though the context of sustained underperformance and negative profitability provides backdrop for investor evaluation.

CFO Bodenstedt sells 87.8K shares (87,795) over 2 days for $1.7M, continuing a pattern of well-timed sells at MLTX

Matthias Bodenstedt (CFO) executed 2 separate sales totaling 87,795 shares for $1,663,934.55, reducing his post-transaction holdings to 1,188,510 shares (-6.9% from prior holdings of 1,276,305). The sales at $18.94 and $19.51 occurred as the stock trades at $17.96, down 71.0% from its 52-week high of $61.99. Critically, Bodenstedt's prior 2 sales at MLTX (2023-12-20 and 2023-12-19) achieved a 90-day well-timed rate of 100%, with the stock declining 13.3% and 18.0% respectively after those sales. The current sale follows this established pattern at a ticker where the company remains unprofitable (net income: $-69,729,000). The timing signal is significant: across his SAME-TICKER HISTORY at MLTX, all 3 prior trades have been well-timed, and the company's fundamentals remain challenged. While the current stock price has risen 0.7% in the past 30 days, the 90-day outcome (which would include the window during which CFO conviction is typically measurable) remains to be seen.

CFO Bodenstedt buys 10.9K shares of MLTX at $9.09 amid -84.9% 52-week decline, unprofitable financials

Chief Financial Officer Matthias Bodenstedt purchased 10,870 shares at $9.09 on 2025-10-08, expanding his holdings from 616,666 to 627,536 shares. The purchase occurs at $9.09 while the current price is $9.38, but critically the stock has collapsed 84.9% from its 52-week high of $61.99 and declined 83.5% over the prior 30 days. MoonLake Immunotherapeutics reported a net loss of $55.2M on a $494.3M market cap, indicating severe unprofitability. While Bodenstedt's cross-ticker track record shows 100% well-timed sells at the 90-day mark, his same-ticker history at MLTX (two sells in December 2023, both well-timed on the downside) and the current fundamental distress suggest this insider purchase occurs in a deeply challenged context rather than a value-recognition signal.